We sought to investigate the real-world impact of sodiumglucose cotransporter 2 inhibitor (SGLT2i) and glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in individuals with type 1 diabetes in relation to effect on blood glucose levels, adverse events and cardio-renal outcomes
For the healthcare professional, understanding these emerging targets is key to anticipating future treatment paradigms
Medications for Cardiovascular Conditions Diuretics , (e.g., Furosemide) often used to manage edema or hypertension, can lead to dehydration, a concern given semaglutides tendency to cause vomiting and diarrhea
Early results are promising, especially if its combined with HT
Persistent or severe vomiting, or inability to tolerate fluids, requires medical attention due to dehydration risk
The CIR Expert Panel has confirmed this ingredient to be nontoxic and clinical studies show no sensitization at cosmetic use concentrations